Sandy Wong, MD, University of California, Los Angeles, CA, talks on the possibility of using anti-myeloma agents in amyloidosis. Dr Wong explains that due to differences in disease biology, anti-myeloma agents can have a very different toxicity profile in patients with amyloidosis, and it is therefore important to conduct studies to evaluate the tolerability of these drugs in amyloidosis. According to Dr Wong, patient selection is critical when considering the possibility of treating amyloidosis patients with CAR-T therapy or T-cell engagers. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.